SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9 at 10:25 a.m. ET in New York, NY.
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update … […]
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results and provided a business update … […]
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) — Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the presentation of three ?posters at the upcomi… […]
Copyright © 2021 Biotech Networks, LLC
